Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 07 Jun 2016 Results assessing efficacy and safety, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University: CALGB80802).
- 19 Nov 2012 Planned end date changed from 1 Sep 2011 to 1 Jun 2017 as reported by ClinicalTrials.gov record.